DFP-10917

DRUG3 trials

Sponsors

Delta-Fly Pharma, Inc.

Conditions

Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaLeukemia, Myeloid, Acute

Phase 1

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

CompletedNCT01702155

Delta-Fly Pharma, Inc.Acute Lymphocytic Leukemia, Acute Myeloid Leukemia

Start: 2012-10-10End: 2017-10-11Updated: 2019-10-25

DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

RecruitingNCT06382168

Delta-Fly Pharma, Inc.Leukemia, Myeloid, Acute

Start: 2024-06-12End: 2026-06-30Target: 39Updated: 2025-09-03

Phase 3

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

TerminatedNCT03926624

Delta-Fly Pharma, Inc.Leukemia, Myeloid, Acute

Start: 2019-11-22End: 2026-01-07Updated: 2026-01-22

Related Papers

Ongoing Phase III Randomized Trial of Salvage DFP-10917 Vs. Non-Intensive Reinduction or Intensive Reinduction for Acute Myelogenous Leukemia (AML)

Blood2023-11-02

Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study

Blood2016-12-025 citations

Abstract 4633: The DNA strand breaking nucleoside analogue sapacitabine sensitizes Brca2-deficient ovarian cancer cells and synergizes with PARP inhibitors

Cancer Research2016-07-15

Abstract 2551: Brca1-deficient ovarian cancer cells are sensitized to the DNA-strand-breaking nucleoside analog sapacitabine that synergizes with PARP inhibition

Cancer Research2015-08-01

First report of a phase I/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia.

Journal of Clinical Oncology2015-05-202 citations